Prescribing Amitriptyline

Why Amitriptyline Still Matters

Amitriptyline is one of the oldest antidepressants still in daily use, and by one measure that deserves respect, it is the most powerful one we have. In the largest network meta-analysis of antidepressants ever assembled, the 2018 Lancet study of 522 trials and over 116,000 patients across 21 drugs, amitriptyline ranked highest in efficacy (odds ratio 2.13 versus placebo), above every SSRI and SNRI on the market. It inhibits reuptake of both norepinephrine and serotonin, a mechanism that predated the SSRIs by three decades and still outperforms them in the sickest depressions.

So why has it retreated to second- and third-line status? The first reason is a good one: side effects. Amitriptyline is the most anticholinergic of the tricyclics, it is sedating, it causes orthostasis and weight gain, and in that same Lancet analysis it sat near the bottom for acceptability, with among the highest dropout rates in the class. The other reason is deadlier: amitriptyline is the single most dangerous antidepressant in overdose. In a National Poison Data System analysis of all 48 FDA-approved antidepressants, it had the highest morbidity index of any antidepressant (345 per 1,000) and caused the most total antidepressant deaths, though its per-exposure mortality index (3.8 per 1,000) was actually well below desipramine's and amoxapine's. A tricyclic overdose is a cardiac emergency, and that fact governs how you prescribe this drug.

Outside psychiatry, though, amitriptyline has become indispensable. By consensus it is the best prophylactic agent for chronic migraine and tension headache. Rheumatologists still call tricyclics first-choice agents for fibromyalgia. For neuropathic pain the number-needed-to-treat is about 3, which beats duloxetine and leaves the SSRIs far behind. It is more effective than SSRIs for irritable bowel syndrome. And for the depressed patient who also has migraines, chronic pain, or insomnia, amitriptyline is a "twofer" that no cleaner molecule can match.

Part 1: Indications

FDA-Approved Use

• Major depressive disorder

That's the sole FDA indication. In 2020s practice, though, you usually reach for amitriptyline for one of its off-label uses, or, best of all, for a patient with both a mood problem and a pain or headache problem you can treat with one drug.

The Evidence-Based Clinical Uses

Major depressive disorder: the most efficacious antidepressant, but not first-line

In the 2018 Lancet network meta-analysis (Cipriani et al., 21 drugs, 116,477 patients), amitriptyline ranked #1 in efficacy (OR 2.13 vs placebo) yet near the bottom in acceptability (high dropout from side effects). In practice, that means amitriptyline is not where you start an uncomplicated depression, but it is a serious option for depression that has failed better-tolerated drugs, and a strong one for the subtypes below.

Melancholic depression

Patients with melancholic features (pervasive anhedonia, ruminative guilt, appetite and weight loss, early-morning awakening, marked psychomotor change) respond better to tricyclics than to SSRIs. Melancholic depression is one of the clearest cases of an older drug beating the newer ones.

Depression with chronic pain

Here amitriptyline does better than SSRIs and roughly as well as duloxetine. When depression and pain travel together, it treats both through a shared mechanism.

Neuropathic pain (off-label, strongly evidence-supported)

Tricyclics relieve neuropathic pain independently of their antidepressant effect, via descending serotonergic/noradrenergic pain-modulating pathways and likely sodium-channel and NMDA effects. The Cochrane number-needed-to-treat is about 3, better than duloxetine (NNT ~5) and far better than SSRIs. Effective doses are typically well below antidepressant doses.

Migraine and tension-type headache prophylaxis (off-label)

Amitriptyline is, by track record and trial data, the best prophylactic agent for chronic migraine and tension-type headache. It has the strongest effect on headache frequency and intensity of any antidepressant class, ahead of SSRIs, SNRIs, bupropion, and mirtazapine. Effective doses are low: 10–75 mg at bedtime, sometimes as little as 10 mg.

Fibromyalgia (off-label)

Despite FDA approval of newer agents (duloxetine, pregabalin, milnacipran), most rheumatologists still recommend tricyclics as first-choice agents. Amitriptyline (with cyclobenzaprine) is the most-studied. At 25–50 mg QHS it improves pain, sleep, and fatigue. Low-dose amitriptyline actually beats duloxetine for the insomnia and fatigue components (duloxetine edges it on mood). Response rates are modest, so treat it as one pillar of a multimodal plan that includes exercise and CBT.

Irritable bowel syndrome (off-label)

Amitriptyline and imipramine outperform SSRIs for IBS, likely via anticholinergic gut effects plus central pain modulation.

Insomnia (off-label, low dose)

Long used as a hypnotic at low doses, especially when insomnia rides with pain. In the elderly, low-dose trazodone or low-dose doxepin has largely displaced it because of the anticholinergic burden.

Where Amitriptyline Falls Short or Is Contraindicated

• Bipolar depression. Tricyclics rank near the top of all antidepressants for inducing mania and mixed states. Avoid in bipolar disorder, or use only with a mood stabilizer on board.
• Anorexia nervosa. Ineffective for weight gain, weight maintenance, and depressive symptoms in double-blind placebo-controlled trials. Don't use it here.
• Bulimia nervosa. Amitriptyline 150 mg/day was no better than placebo in a controlled trial; if you want a tricyclic for bulimia, imipramine and desipramine have the better data.
• OCD. Among tricyclics, only clomipramine has real OCD evidence (its strong serotonergic action). Amitriptyline is not the tricyclic for OCD.
• Borderline personality disorder. Risky: high overdose lethality plus signal that it may trigger aggression and disinhibition. Avoid.

Part 2: Before You Start: Workup and Candidacy

Amitriptyline's workup is short but non-negotiable on two points: cardiac screening and overdose-risk screening.

Baseline Assessment

Who Is a Poor Candidate?

• Actively suicidal or impulsive patients (overdose lethality): safer alternatives exist
• Borderline personality disorder: lethality plus disinhibition risk
• Bipolar disorder without a mood stabilizer: mood-switch risk
• Significant cardiac conduction disease, recent MI, long QT: Class I effects
• The frail elderly / anyone with cognitive impairment: anticholinergic burden; prefer nortriptyline/desipramine or a non-tricyclic
• Untreated narrow-angle glaucoma, significant urinary retention/BPH, severe chronic constipation: anticholinergic effects worsen all three
• Uncontrolled seizure disorder: lowered threshold

Mild, well-controlled versions of these (e.g., stable coronary disease, treated glaucoma) are relative, not absolute, cautions. Weigh them.

Part 3: How to Start and Dose

Formulation

Amitriptyline is available generically as oral tablets in a wide range of strengths (commonly 10, 25, 50, 75, 100, and 150 mg), which makes gentle titration easy, and it is cheap. Because it is sedating, the entire daily dose is given at bedtime in nearly all indications. The sedation then helps the patient sleep, and the peak anticholinergic and orthostatic effects land overnight instead of during the day.

Start Low, Go Slow

Tolerability depends almost entirely on titration speed. Raise the dose no faster than every 5–7 days, and start lower still in the elderly, the medically frail, and pain/headache patients (who need far less than depression patients). When a dose makes a patient quit, it is usually the starting dose that was too high, not the target dose.

Dosing by Indication

Major depressive disorder

• Start: 25–50 mg QHS. In sensitive or older patients, start 10 mg.
• Titrate by 25 mg every 5–7 days as tolerated.
• Typical effective range: 150–250 mg/day (given at bedtime). Unlike SSRIs, tricyclics show a real dose-response relationship: higher doses do add antidepressant effect, so don't under-treat a depression by parking at 50 mg.
• Give an adequate trial at an adequate dose before calling it a failure.

Migraine / tension-type headache prophylaxis

• Start: 10 mg QHS (1–2 hours before bed).
• Target: 10–75 mg QHS. Many patients respond at 10–25 mg; there's usually no need to reach depression-range doses.

Neuropathic pain / depression with chronic pain

• Start: 10–25 mg QHS.
• Titrate by 10–25 mg every 1–2 weeks to effect.
• Pain relief often occurs at 25–75 mg, below antidepressant doses. If you're treating both depression and pain, titrate toward the antidepressant range.

Fibromyalgia

• Start: 5–10 mg QHS.
• Titrate by 5 mg per week until symptom improvement or troublesome side effects.
• Target: 25–50 mg QHS. Position it as one part of a multimodal plan (exercise, CBT).

Insomnia (off-label)

Low doses (often 10–25 mg QHS). Weigh the anticholinergic burden, especially in older adults, where trazodone 25 mg or low-dose doxepin is preferable.

Onset

Sedation and anticholinergic effects appear the first night. Analgesic and headache-prophylactic benefits often emerge within 1–2 weeks. Full antidepressant effect, as with any antidepressant, takes 4–6 weeks at an adequate dose.

Dose Adjustments and Special Populations

• Geriatric: start 10 mg QHS and titrate slowly to a lower final dose. Amitriptyline is among the most anticholinergic TCAs (confusion, falls, urinary retention, and constipation are common), and it appears on the Beers list; prefer nortriptyline or a non-TCA when a tricyclic isn't essential.
• Hepatic impairment: hepatically metabolized (CYP2D6/2C19); use lower doses, titrate cautiously, and consider a serum level.
• Renal impairment: no fixed dose adjustment, but active metabolites can accumulate, so use caution in significant impairment.
• Cardiac disease: get a baseline ECG in patients over 40 or with cardiac history; avoid after recent MI and in significant conduction disease. TCAs slow cardiac conduction (widened QRS/QTc), and overdose is cardiotoxic and a leading cause of antidepressant-overdose death. Keep that in mind in patients at suicide risk (limited quantities, close follow-up).
• Pediatric: not recommended for depression under age 12; the historical enuresis use has largely been abandoned in favor of safer options.

Stopping and Switching

• Discontinuation: taper gradually (over at least 2 weeks), because abrupt withdrawal produces cholinergic rebound (nausea, malaise, sweating, insomnia, vivid dreams).
• MAOI washout: allow 14 days in each direction between amitriptyline and an MAOI.

Part 4: Monitoring

Amitriptyline's monitoring is lighter than lithium's (there is no mandatory ongoing lab), but it is not zero.

Cardiac

• Baseline ECG if age >40 or any cardiac history: document QTc and conduction.
• Repeat ECG if you push to high antidepressant doses, add an interacting/QT-prolonging drug, or the patient develops palpitations, syncope, or dizziness.
• In a healthy patient on low doses for pain/headache, serial ECGs are generally unnecessary after a normal baseline.

Serum Levels (optional for amitriptyline)

Unlike nortriptyline, imipramine, and desipramine, the three tricyclics with therapeutic windows that are actually useful, amitriptyline doesn't need routine levels. They are worth checking when:

• A drug interaction may have raised levels (adding a CYP2D6/2C19 inhibitor)
• Metabolism is in question (non-response at a high dose, or toxicity at a low dose)
• You suspect nonadherence or toxicity

Target: combined amitriptyline + nortriptyline (its active metabolite) of 80–200 ng/mL, with ~300 ng/mL the laboratory alert level. Draw the level 8–12 hours after the last dose, and only after at least 5 half-lives at a stable dose, which for the combined level means about a week.

Clinical Monitoring at Every Visit

• Anticholinergic review: dry mouth, constipation, urinary hesitancy, blurred vision, confusion. In older patients, actively screen for the downstream complications: dental decay, bowel obstruction, UTI from retention.
• Orthostatic vitals early and after dose increases, especially in the elderly and fall-prone.
• Weight.
• Mood switch: watch for emerging hypomania/mania, particularly if bipolarity was ever a question.
• Bowel function: confirm the regimen is working.

Routine LFTs are not recommended: hepatotoxicity is extremely rare (~4 per 100,000 patient-years).

Part 5: Side Effects and How to Manage Them

The principle mirrors lithium's: most amitriptyline side effects are dose-dependent, many attenuate over weeks, and nearly all are manageable. Manage them early and proactively, because patients quit this drug over side effects, not lack of efficacy, and its high efficacy does nothing for a patient who stops in week two.

Anticholinergic (Amitriptyline's Characteristic Problem)

Amitriptyline is the most anticholinergic tricyclic. Expect dry mouth, constipation, urinary hesitancy/retention, blurred vision, and, especially in the elderly, confusion.

Management:

• Dry mouth: sugar-free gum or lozenges, frequent sips of water, good dental hygiene (chronic dry mouth accelerates decay). Reassure that it often eases over weeks.
• Constipation: get ahead of it. Start a bowel regimen up front: adequate fluids, fiber, and a stool softener (docusate) ± an osmotic laxative (polyethylene glycol) as needed. In the elderly, unmanaged constipation can progress to bowel obstruction.
• Urinary retention: ask about hesitancy; be especially alert in men with BPH. Retention can seed UTIs in older patients.
• Blurred vision: usually tolerable and transient; reassure. Screen for narrow-angle glaucoma before starting: anticholinergics can precipitate an attack.
• Confusion/cognitive dulling: most concerning in older adults. Lower the dose, or, better, switch to a secondary amine (nortriptyline or desipramine), which carry a fraction of the anticholinergic load. Anticholinergic burden is associated with increased dementia risk over time.

Cardiovascular

• Orthostatic hypotension / falls: driven by alpha-adrenergic blockade; a major hazard in the elderly. Check orthostatic vitals, educate about slow position changes and hydration, start low, and prefer a secondary amine when fall risk is high (nortriptyline causes the least orthostasis of the class).
• Cardiac conduction / arrhythmia: Class I antiarrhythmic (quinidine-like) effects slow conduction and can prolong QT. Rarely a problem at therapeutic doses in a normal heart, but it is the reason for the baseline ECG and for caution with QT-prolonging comedications. The same property makes overdose lethal (Part 6).

Sedation

Common and often useful: dose at bedtime and it aids sleep. If daytime grogginess persists, lower the dose or shift more of it earlier in the evening; if still limiting, consider a less sedating secondary amine.

Weight Gain

TCAs, and amitriptyline in particular, promote weight gain (appetite stimulation via histamine/serotonergic effects). Secondary amines carry somewhat less risk. Counsel on diet and activity early; weigh at visits; if weight becomes limiting, reconsider the agent.

Sexual Dysfunction

A class effect. Tertiary amines like amitriptyline tend toward more overall sexual dysfunction. Options: dose reduction, timing changes, or switching within or outside the class if adherence is threatened.

Neurologic

• Seizure threshold is lowered, relevant in seizure-prone patients, TBI, and overdose.
• Fine tremor can occur; usually mild.

Photosensitivity

TCAs can cause photosensitivity; counsel sun protection (SPF >30) in patients with significant exposure.

The Pretreatment / Comfort Menu (set up on day one)

• Constipation: docusate ± PEG 3350; fluids and fiber
• Dry mouth: sugar-free gum/lozenges, xylitol products, dental care
• Orthostasis: slow position changes, hydration, orthostatic checks
• Sedation: bedtime dosing (so it helps sleep)

Part 6: Overdose and Toxicity

Overdose toxicity is the defining safety issue with amitriptyline and what separates it from the SSRIs. Keep it in mind every time you write the prescription.

Morbidity and Mortality

Amitriptyline is the most dangerous antidepressant in overdose. In the National Poison Data System analysis of all 48 FDA-approved antidepressants (Nelson & Spyker, Am J Psychiatry 2017):

• Morbidity index: 345 per 1,000: roughly 1 in 3 amitriptyline overdoses causes serious injury requiring hospitalization and cardiac monitoring.
• Mortality index: 3.8 per 1,000: about 0.38% of overdoses are fatal.
• It had the highest morbidity index of any antidepressant studied and caused the most total deaths, though on a per-exposure basis desipramine and amoxapine had higher mortality indices.

The mechanism is the Class I (quinidine-like) sodium-channel blockade behind the drug's cardiac profile. In overdose it produces QRS widening, dangerous arrhythmias, hypotension, seizures, coma, and cardiac collapse. Anticholinergic toxicity (delirium, hyperthermia, mydriasis, urinary retention) accompanies it.

Clinical Progression of Overdose

1. Early: anticholinergic signs (dry mouth, mydriasis, tachycardia, agitation/confusion), drowsiness.
2. Progressive: worsening tachycardia, QRS widening, hypotension, hyperthermia.
3. Severe: wide-complex arrhythmias, seizures, coma, cardiovascular collapse.

QRS width on the ECG is the main prognostic marker: the wider the QRS, the higher the risk of seizures and ventricular arrhythmia.

Management

ED management centers on serum alkalinization with sodium bicarbonate (which narrows the QRS and counters the sodium-channel blockade), continuous cardiac monitoring, airway/seizure management, and supportive care. (This is for orientation. Do not attempt to manage a tricyclic overdose outside an emergency setting.)

What This Means When You Prescribe

• Screen every candidate for overdose risk before prescribing.
• In any at-risk patient, dispense small quantities, as little as a weekly supply, so no single fill is lethal.
• Involve family in storing and dispensing when risk is elevated.
• Prefer a safer antidepressant (SSRI, SNRI, or mirtazapine) when suicide risk is a live concern.

Boxed Warning

Part 7: Drug Interactions

Pharmacodynamic: Additive Risks

• QT-prolonging / conduction-slowing drugs (certain antipsychotics, antiarrhythmics, some antibiotics, methadone): additive cardiac risk. Review the full list before combining.
• Other anticholinergics (antihistamines, antiparkinsonian agents, bladder antimuscarinics, some antipsychotics): additive anticholinergic burden (delirium, retention, obstipation). Watch this especially in the elderly.
• CNS depressants / alcohol: additive sedation.
• MAOIs: the classic dangerous combination, with risk of serotonin syndrome and hypertensive crisis. Separate by an adequate washout (generally ≥14 days).
• Sympathomimetics: potential for hypertensive response.
• Serotonergic agents: serotonin syndrome risk with any serotonergic combination; amitriptyline is a serotonin reuptake inhibitor, so respect the additive load.

Pharmacokinetic: CYP450

Amitriptyline is metabolized hepatically (chiefly CYP2C19 to nortriptyline, then CYP2D6). Strong CYP2D6/2C19 inhibitors raise amitriptyline levels toward the toxic range.

• Potent inhibitors that raise TCA levels: paroxetine, fluoxetine, fluvoxamine, bupropion, duloxetine, cimetidine, quinidine. When you add one of these, or add amitriptyline on top of one, start low, titrate slowly, and consider a serum level.
• Antidepressants that do NOT meaningfully raise TCA levels (safer to combine): citalopram, escitalopram, desvenlafaxine, mirtazapine, trazodone, vilazodone, vortioxetine. Use these when you need to augment or co-prescribe.

A Note on Triptans

An old FDA alert (2006) warned about serotonin syndrome when triptans are combined with serotonergic antidepressants. That alert rested on only 27 cases over 5 years, and the combination is used routinely and safely in millions of migraine patients. Expert consensus is that withholding a triptan from a patient on amitriptyline out of serotonin-syndrome fear is generally unjustified. Use reasonable caution and counsel on symptoms, but the combination is not contraindicated. That matters, because amitriptyline is a first-line migraine preventive.

A Note on NSAIDs

Unlike lithium, amitriptyline has no dangerous pharmacokinetic interaction with NSAIDs. In fibromyalgia, amitriptyline plus naproxen outperformed placebo while naproxen alone did not, so the combination appears complementary.

Part 8: Special Populations

Pregnancy

Tricyclics, including amitriptyline, are among the better-characterized antidepressants in pregnancy, with decades of use and no consistent signal for major malformations. The decision is the familiar one: weigh the drug's risks against the substantial risks of untreated depression (which harms both mother and fetus). Coordinate with obstetrics. If amitriptyline is controlling a severe depression or disabling pain/headache, continuing it is often the right call; watch the neonate for transient anticholinergic/withdrawal effects (jitteriness, feeding difficulty, urinary retention) near delivery.

Lactation

Amitriptyline and its metabolite pass into breast milk in low concentrations, and it has generally been considered relatively compatible with breastfeeding, with infant serum levels typically low or undetectable. Still, monitor the infant for sedation, poor feeding, and irritability, and coordinate with pediatrics.

Elderly

Older patients call for the most caution with amitriptyline. It is the most anticholinergic tricyclic, is on the Beers criteria, and carries the highest burden of falls (orthostasis), confusion, urinary retention, constipation, and dementia risk.

• Prefer a secondary amine (nortriptyline or desipramine) when a tricyclic is really needed (e.g., neuropathic pain, melancholic depression). Nortriptyline is the first choice for fall risk (least orthostasis) and has a usable therapeutic window (50–150 ng/mL).
• For insomnia, low-dose trazodone (25 mg) or low-dose doxepin (3–6 mg) has replaced low-dose amitriptyline.
• If you must use amitriptyline, start very low (10 mg), titrate slowly, get a baseline ECG, check orthostatics, and put a bowel regimen in place from day one.

Renal Impairment

Amitriptyline is hepatically metabolized, so dose adjustment for renal impairment is generally not required; however, use standard start-low caution and be alert to accumulation of metabolites in severe impairment.

Hepatic Impairment

Because clearance is hepatic, significant liver disease impairs metabolism and raises levels. Use lower doses, titrate more cautiously, and consider serum-level monitoring. Severe hepatic disease is a relative contraindication.

Children and Adolescents

Tricyclics in youth carry FDA cautions regarding suicidality (the boxed warning) and have a documented cardiac-safety concern, including rare reports of sudden death, which historically prompted ECG monitoring in pediatric tricyclic use. Efficacy data for childhood depression are weak. Amitriptyline is used in pediatrics mainly for specific indications (e.g., migraine, functional abdominal pain) by clinicians experienced in that use, with cardiac screening. It is not a routine pediatric antidepressant.

Part 9: Discontinuation

Amitriptyline is generally easier to discontinue than the short-half-life SNRIs (venlafaxine, duloxetine) and paroxetine, but it should still be tapered, not stopped abruptly, for two reasons:

1. Cholinergic rebound. Abrupt withdrawal of a strongly anticholinergic drug produces a cholinergic-rebound syndrome: nausea, cramping, diarrhea, sweating, malaise, insomnia, vivid dreams, and flu-like symptoms. Amitriptyline's high anticholinergic potency makes this more likely than with cleaner tricyclics.
2. Relapse. As with any antidepressant, stopping too fast risks return of depression (or of the pain/headache you were controlling).

How to stop:

• Taper gradually over several weeks, guided by dose and duration of use, slower for higher doses and long-term users (e.g., reduce by ~25 mg every 1–2 weeks, going slower near the end).
• Monitor for cholinergic-rebound symptoms and for return of the underlying condition; slow the taper if either emerges.
• For a patient stopping to switch to an MAOI, respect the required washout.

Abrupt withdrawal of tricyclics has also rarely been associated with withdrawal-emergent dyskinesias (typically within weeks), another reason to come off slowly.

Part 10: Amitriptyline vs the Alternatives

vs other tricyclics: the most useful comparison

This is often the most useful comparison, because switching within the class solves amitriptyline's main problems:

• Nortriptyline (amitriptyline's own secondary-amine metabolite): far less anticholinergic and orthostatic, better tolerated, has a clean therapeutic window (50–150 ng/mL), and is the tricyclic of choice for the elderly, fall-prone patients, and headache when tolerability matters.
• Desipramine: least anticholinergic, flexible dosing, good for TRD; serum level >125 ng/mL.
• Clomipramine: the tricyclic for OCD (most serotonergic).
• Doxepin: the tricyclic for insomnia (potent antihistamine); FDA-approved at ultra-low doses (3–6 mg) as a hypnotic.
• Amitriptyline's own edge: the longest track record and best trial data for pain and headache, and top-ranked antidepressant efficacy, at the cost of being the most anticholinergic and most toxic in overdose.

Mechanism

Amitriptyline is a tertiary-amine tricyclic that inhibits reuptake of both norepinephrine and serotonin, the mechanism Julius Axelrod's work first illuminated in the 1950s, decades before the SSRIs. Its therapeutic and adverse effects come from a broad receptor profile:

• NE + 5-HT reuptake inhibition → antidepressant and (via descending spinal pain pathways) analgesic effects. It also down-regulates NMDA receptor activity and modulates sodium channels, which contributes to its neuropathic-pain efficacy independent of mood.
• Potent muscarinic (anticholinergic) antagonism → dry mouth, constipation, retention, blurred vision, confusion (amitriptyline's is the strongest of the class).
• H1-histamine antagonism → sedation and weight gain.
• Alpha-1-adrenergic antagonism → orthostatic hypotension.
• Class I (quinidine-like) sodium-channel blockade in cardiac tissue → conduction slowing therapeutically, and lethal arrhythmias in overdose.

That last property sums up the drug's safety problem: the same sodium-channel effect that helps calm neuropathic pain is what stops the heart in overdose.

Amitriptyline is metabolized in the liver (CYP2C19 → nortriptyline, its active secondary-amine metabolite; CYP2D6 further clears both). That is why CYP inhibitors raise its levels and why combined amitriptyline-plus-nortriptyline is the number you check.

The Bedside Cheat Sheet